The Drug Enforcement Administration (DEA) recently announced plans to host two public listening sessions on September 12 and 13, 2023. The purpose of these sessions is to gather further input on the practice of telemedicine, with an emphasis on the remote prescribing of controlled substances without an in-person evaluation of patients beforehand.
The meetings will be held at the DEA’s headquarters in Arlington, Virginia. This initiative follows the significant shift towards remote healthcare services, triggered by the COVID-19 pandemic. The scheduled sessions underscore the persistent regulatory and legal challenges inherent in this evolving sector.
The key issue at stake is how to effectively and efficiently regulate the remote prescribing of controlled substances, while also ensuring the highest level of medical safety. Balancing patient care, accessibility, and legal controls in a rapidly digitizing world presents a daunting task for stakeholders.
Telemedicine, including remote consultations and prescriptions, has proven to be an essential healthcare service, particularly in the wake of COVID-19. At the same time, the risk of potential misuse of controlled substances prescribed remotely underlines the complexity of developing appropriate regulatory frameworks.
These listening sessions are an important step in capturing diverse perspectives from both practitioners and patients, as well as legal professionals engaged in healthcare and pharmaceutical law. As the DEA continues its mission to protect public health and safety, these sessions offer an open forum for a critical dialogue about these emerging issues.
For additional information on the upcoming DEA listening sessions, refer to the original announcement provided by Epstein Becker & Green
here.